The Research Brief is a short take about interesting academic work.
The big idea
The scientific community worldwide has mobilized with unprecedented speed to tackle the COVID-19 pandemic, and the emerging research output is staggering. Every day, hundreds of scientific papers about COVID-19 come out, in both traditional journals and non-peer-reviewed preprints. There’s already far more than any human could possibly keep up with, and more research is constantly emerging.
And it’s not just new research. We estimate that there are as many as 500,000 papers relevant to COVID-19 that were published before the outbreak, including papers related to the outbreaks of SARS in 2002 and MERS in 2012. Any one of these might contain the key information that leads to effective treatment or a vaccine for COVID-19.
Traditional methods of searching through the research literature just don’t cut it anymore. This is why we and our colleagues at Lawrence Berkeley National Lab are using the latest artificial intelligence techniques to build COVIDScholar, a search engine dedicated to COVID-19. COVIDScholar includes tools that pick up subtle clues like similar drugs or research methodologies to recommend relevant research to scientists. AI can’t replace scientists, but it can help them gain new insights from more papers than they could read in a lifetime.
COVIDScholar is a search engine with machine learning algorithms under the hood. Screen capture by The Conversation
Why it matters
When it comes to finding effective treatments for COVID-19, time is of the essence. Scientists spend 23% of their time searching for and reading papers. Every second our search tools can save them is more time to spend making discoveries in the lab and analyzing data.
AI can do more than just save scientists time. Our group’s previous work showed that AI can capture latent scientific knowledge from text, making connections that humans missed. There, we showed that AI was able to suggest new, cutting-edge functional materials years before their discovery by humans. The information was there all along, but it took combining information from hundreds of thousands of papers to find it.
We are now applying the same techniques to COVID-19, to find existing drugs that could be repurposed, genetic links that might help develop a vaccine or effective treatment regimens. We’re also starting to build in new innovations, like using molecular structures to help find which drugs are similar to each other, including those that are similar in unexpected ways.
How we do this work
The most important part of our work is the data. We’ve built web scrapers that collect new papers as they’re published from a wide variety of sources, making them available on our website within 15 minutes of their appearance online. We also clean the data, fixing mistakes in formatting and comparing the same paper from multiple sources to find the best version. Our machine learning algorithms then go to work on the paper, tagging it with subject categories and marking work important to COVID-19.

COVIDScholar labels and categorizes about 250 journal papers a day to help researchers make connections they might otherwise miss. Kevin Cruse and Haoyan Huo, CC BY-ND
We’re also continuously seeking out experts in new areas. Their input and annotation of data is what allows us to train new AI models.
What’s next
So far, we have assembled a collection of over 60,000 papers on COVID-19, and we’re expanding the collection daily. We’ve also built search tools that group research into categories, suggest related research and allow users to find papers that connect different concepts, such as papers that connect a specific drug to the diseases it’s been used to treat in the past. We’re now building AI algorithms that allow researchers to plug search results into quantitative models for studying topics like protein interactions. We’re also starting to dig through the past literature to find hidden gems.
We hope that very soon, researchers using COVIDScholar will start to identify relationships that they might never have imagined, bringing us closer to treatments and a remedy for COVID-19.


Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters
Trump Signs Executive Order to Establish National AI Regulation Standard
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Australia’s Under-16 Social Media Ban Sparks Global Debate and Early Challenges
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 



